-
61.发明公开
公开(公告)号：EP3711762A1
公开(公告)日：2020-09-23
申请号：EP20173231.0
申请日：2014-09-10
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , UNIVERSITE CLAUDE BERNARD - LYON 1 , ENS - Ecole Normale Supérieure de Lyon , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) , EDELRIS , Poxel
发明人： ANDRE, Patrice , LOTTEAU, Vincent , RADREAU, Pauline , GILARDONE, Marine , PATIN, Amaury , ROCHE, Didier , CRAVO, Daniel , HALLAKOU-BOZEC, Sophie
IPC分类号： A61K31/42 , A61K31/453 , A61K31/575 , A61K31/4525 , A61K31/496 , A61K31/513 , A61K31/522 , A61K31/55 , A61K31/551 , A61K31/675 , A61K31/7072 , A61K38/21 , A61K45/06 , A61P1/16 , A61P31/12 , A61P31/20
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.
-
公开(公告)号：EP3571834A1
公开(公告)日：2019-11-27
申请号：EP17822691.6
申请日：2017-12-22
申请人： SORBONNE UNIVERSITE , Universite Pierre et Marie Curie (UPMC) , Universite Paris Diderot - Paris 7 Diderot Valoris , Ecole Normale Supérieure de Paris , Université de Bourgogne
发明人： DARSON, David , DUBOIS, Julien , HEYRMAN, Barthélémy , GINHAC, Dominique , BOUDERBANE, Mustapha
IPC分类号： H04N5/235 , H04N5/353 , H04N5/355 , H04N5/372 , H04N5/3745
-
公开(公告)号：EP3526864A1
公开(公告)日：2019-08-21
申请号：EP17743076.6
申请日：2017-05-05
申请人： Centre National de la Recherche Scientifique , Université Paris Diderot Paris 7 , SORBONNE UNIVERSITE , Ecole Normale Supérieure
发明人： DHILLON, Sukhdeep , NONG, Hanond , WANG, Feihu , FOBBE, Tobias , JUKAM, Nathan
-
公开(公告)号：EP3526294A1
公开(公告)日：2019-08-21
申请号：EP17793714.1
申请日：2017-10-13
申请人： Etablissements Tiflex , Université Claude Bernard Lyon 1 , Centre National de la Recherche Scientifique , Ecole Normale Supérieure de Lyon
IPC分类号： C09D11/102 , B41M5/00 , C09D11/101
-
公开(公告)号：EP2760844B1
公开(公告)日：2018-11-21
申请号：EP12775783.9
申请日：2012-09-27
IPC分类号： C07D239/91 , C07D401/12 , C07D403/12 , C07D417/14 , C07K5/10 , C07K7/06 , C12Q1/37 , G01N33/533
CPC分类号： C12Q1/37 , C07D239/91 , C07D401/12 , C07D403/12 , C07D417/14 , C07K5/1021 , G01N33/542
-
66.发明公开
公开(公告)号：EP3390388A1
公开(公告)日：2018-10-24
申请号：EP16831494.6
申请日：2016-12-16
申请人： Ecole Normale Supérieure de Lyon , Centre National de la Recherche Scientifique , Université Claude Bernard Lyon I , Commissariat à l'Énergie Atomique et aux Énergies Alternatives
IPC分类号： C07D401/14 , C07F5/00 , G01N23/223 , G01N33/58 , C07D413/14 , B01D9/00
CPC分类号： C07F5/003 , B01D9/005 , C07D401/14 , C07D413/14 , C30B7/14 , C30B29/58 , G01N23/223
摘要： The invention relates to cationic complexes made up of a lanthanide ion Ln3+ and a ligand of formula (I) with X, Y and R1 as defined in claim 1, and to the salts thereof with an anion, the solvates and hydrates thereof; with the exception of cationic complexes made up of a lanthanide ion Ln3+ and a ligand of one of formulae (1.1) or (1.4) as defined in claim 1, and the salts, solvates and hydrates thereof. The invention also relates to the use of such a complex or of a cationic complex made up of a lanthanide ion Ln3+ and a ligand of formula (1.1) or (1.4) as defined in claim 1, or of one of the salts thereof with an anion, the solvates or hydrates thereof, as an aid to the crystallisation of a biological macromolecule, as well as to crystallisation methods and methods for analysing or determining the structure of a biological macromolecule.
-
公开(公告)号：EP3355918A1
公开(公告)日：2018-08-08
申请号：EP16775184.1
申请日：2016-09-27
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , ENS - Ecole Normale Supérieure de Lyon , Université Claude Bernard Lyon 1 , Centre National de la Recherche Scientifique (CNRS) , Hospices Civils De Lyon
发明人： SICARD, Antoine , THAUNAT, Olivier
CPC分类号： A61K47/6939 , A61K39/001 , A61K39/12 , A61K39/21 , A61K39/39 , A61K47/6849 , A61K2039/505 , A61K2039/5154 , A61K2039/55555 , A61K2039/625 , C12N7/00 , C12N2740/16034
摘要： The present invention relates to biofunctionalized nanoparticles and uses thereof in adoptive cell therapy. In particular, the present invention relates to a nanoparticle comprising an amount of at least one antigen and an amount of at least one antibody having specificity for a B cell receptor wherein the antigen and antibody are attached to the surface of the nanoparticle.
-
公开(公告)号：EP3354659A2
公开(公告)日：2018-08-01
申请号：EP18156497.2
申请日：2014-07-30
申请人： URGO RECHERCHE INNOVATION ET DEVELOPPEMENT , Centre National de la Recherche Scientifique CNRS , Université Paris Diderot - Paris 7 , INSERM (Institut National de la Santé et de la Recherche Médicale) , Ecole Normale Supérieure
IPC分类号： C07K14/47 , C12N15/113 , A61K9/00 , A61K45/06 , A61L15/16 , A61K31/197 , A61K31/506 , A61K31/519
CPC分类号： A61K31/519 , A61K9/0014 , A61K31/197 , A61K31/506 , A61K45/06 , A61L15/16 , A61L2300/432 , C07K14/4702 , C12N15/113 , C12N2310/14
摘要： The present invention relates to a therapeutic compound comprising:
- an agent that inhibits the activity of at least one gene selected from the group consisting of MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes
and/or
- an agent that enhances the activity of at least one gene selected from the group consisting of CREB5, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene
for use in the treatment of wounds, preferably chronic wounds.-
公开(公告)号：EP3308452A1
公开(公告)日：2018-04-18
申请号：EP16729235.8
申请日：2016-06-08
申请人： CNAM-CONSERVATOIRE NATIONAL DES ARTS ET METIERS , Centre National de la Recherche Scientifique (CNRS) , Ecole Normale Supérieure de Cachan
CPC分类号： H02K19/103 , H02K1/148 , H02K1/16 , H02K21/046 , H02K21/44 , H02K41/03 , H02K41/033 , H02K2201/15 , H02K2213/12
摘要： The proposed invention is an electric machine with flux switching comprising:- a movable element (20), comprising a plurality of flux switching teeth, and - a stator (10), comprising a plurality of teeth, excitation coils (15) and armature coils, characterized in that the stator is formed of a succession of elementary cells each comprising: - three teeth, comprising a central tooth (120) and two lateral teeth (121), delimiting therebetween two central notches (140), an excitation coil being housed in the central notches and wound around the central tooth, and - two lateral half-notches (141) on either side of the lateral teeth, each half-notch housing at least in part an armature coil, in such a way that two successive elementary cells share a common lateral notch.
-
70.发明公开
公开(公告)号：EP3301112A3
公开(公告)日：2018-04-18
申请号：EP17196300.2
申请日：2014-07-30
申请人： Centre National de la Recherche Scientifique (C.N.R.S.) , INSERM - Institut National de la Santé et de la Recherche Médicale , URGO RECHERCHE INNOVATION ET DEVELOPPEMENT , Université Paris Diderot - Paris 7 , Ecole Normale Supérieure
IPC分类号： C07K14/47 , C12N15/113 , A61K48/00 , A61K31/7088 , A61K45/06 , A61K31/713
摘要： The present invention relates to a therapeutic compound comprising :
- an agent that inhibits the activity of at least one gene selected from the group consisting of FOXS1, CREB5, HIC1, IRF7, POU2F2, STAT4, TCF4, and/or
- an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 for use in the prevention and/or treatment of fibrosis, hypertrophic scar or keloid.
-
-
-
-
-
-
-
-
-
搜索结果
230 条记录 (耗时 0.024 秒)
